| abstract |
Abstract The present invention is based, in part, on the identification of novel human anti-PD-1, PD-Li, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-LI, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD L 1, and PD-L2 antibodies described herein. 4254443_1 (GHMatters) P86720.AU.1 |